Introduction#
Sana Biotechnology, Inc. has announced that it will present preclinical data on its SG293 product candidate at the upcoming American Society of Gene & Cell Therapy Annual Meeting. This event is significant for those interested in advancements in gene and cell therapies.
Presentation Details#
The oral presentation is set for Tuesday, May 12, 2026, from 8:15 to 8:30 a.m. ET in Boston, where the meeting will take place from May 11-15. The presentation, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293," will focus on non-AAV viral vector systems. A CAR-T cell therapy is a type of treatment that modifies a patient's own immune cells to better fight cancer.
About SG293#
SG293 is designed to target CD19, a protein found on the surface of certain cancer cells. This product candidate utilizes a unique delivery technology that aims to insert genetic material directly into CD8+ T cells, which are a type of immune cell. This targeted approach seeks to minimize the impact on other tissues, such as the liver, while effectively generating CAR-T cells to combat B-cell cancers and autoimmune diseases.
Recent Collaborations and Governance Changes#
In addition to the upcoming presentation, Sana Biotechnology has formed a strategic partnership with the Mayo Clinic to advance SC451, a cell therapy aimed at managing type 1 diabetes. This collaboration is expected to improve treatment protocols for patients. Furthermore, the company has made changes to its board of directors to ensure balanced governance, reclassifying Dr. Steven D. Harr to align with its corporate structure. These moves reflect Sana's commitment to both advancing its therapeutic developments and maintaining effective corporate governance.